Key result
TRIM22 knockdown significantly increased the apoptosis rate of U87 glioblastoma cells from 11.03% to 34.6%, demonstrating that TRIM22 promotes tumor development by stabilizing Bcl-2.
Absolute Event Rate: 34.6% vs 11.03%
p-value: p=<0.01
TRIM22 promotes glioblastoma progression by stabilizing Bcl-2, highlighting its potential as a novel therapeutic target for glioma.
No takes yet. Share an insight, caveat, or question.
TRIM22 targeting merits exploration in GBM models; leaves open clinical translation pending in vivo validation.
Zhang et al. (2025) studied Glioblastoma. TRIM22 knockdown vs. Control was evaluated on Apoptosis rate in U87 glioblastoma cells (p=<0.01). TRIM22 knockdown significantly increased the apoptosis rate of U87 glioblastoma cells from 11.03% to 34.6%, demonstrating that TRIM22 promotes tumor development by stabilizing Bcl-2.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: